Meeting
2022 ASCO Gastrointestinal Cancers Symposium
Plasma hPG80 (circulating progastrin) as a novel prognostic biomarker for hepatocellular carcinoma at early to intermediate stages (BCLC 0 to B).
Authors
Alexandre Prieur
ECS-Progastrin, Prilly, Switzerland
Alexandre Prieur , Marie Dupuy , Sarah Iltache , Eric Assenat
Disclaimer
This material on this page is ©2024 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please contact licensing@asco.org
Poster Details
Session Type
Poster Session
Session Title
Poster Session B: Cancers of the Pancreas, Small Bowel, and Hepatobiliary Tract
Track
Pancreatic Cancer,Hepatobiliary Cancer,Neuroendocrine/Carcinoid,Small Bowel Cancer
Sub Track
Tumor Biology, Biomarkers, and Pathology
DOI
10.1200/JCO.2022.40.4_suppl.472
Abstract #
472
Poster Bd #
N1
Abstract Disclosures
Similar Posters
Poster
2021 ASCO Annual Meeting
Prognostic value of plasma hPG80 (circulating progastrin), alone or in combination with Alpha-fetoprotein (AFP) in patients with hepatocellular carcinoma.
First Author: Alexandre Prieur
Poster
2024 ASCO Gastrointestinal Cancers Symposium
Agrin as a prognostic biomarker in hepatocellular carcinoma.
First Author: Ankita Kapoor
Poster
2023 ASCO Annual Meeting
Development and validation of a non-invasive cfDNA targeted sequencing assay for early-stage hepatocellular carcinoma detection using cfDNA methylation and fragmentomics.
First Author: Rui Liu
Poster
2022 ASCO Gastrointestinal Cancers Symposium
Multi-target blood test to improve the performance of hepatocellular carcinoma surveillance programs: A modeling-based virtual trial.
First Author: Jagpreet Chhatwal